转移性激素受体阳性/HER2阴性乳腺癌患者从CDK4/6抑制剂到二线治疗的历程:GIM14/BIOMETA研究中701例患者的真实世界分析
GIM14/BIOMETA研究纳入701例接受一线CDK4/6抑制剂治疗的激素受体阳性/HER2阴性转移性乳腺癌患者,中位随访24.80个月。HER2零表达与低表达亚组的一线治疗至停药时间和总生存无显著差异;内分泌敏感亚组至停药时间优于继发和原发内分泌耐药亚组;239例二线治疗患者中不同方案的二线至停药时间无显著差异。
要点
- HER2零表达与低表达亚组一线CDK4/6抑制剂治疗的至停药时间和总生存均无显著差异。
- 内分泌敏感亚组至停药时间33.24个月,优于继发耐药19.92个月和原发耐药17.40个月(p<0.001)。
- 239例二线治疗患者中,卡培他滨、紫杉类、依维莫司联合依西美坦或氟维司群的二线至停药时间无显著差异。
核心结论
- 内分泌治疗联合CDK4/6抑制剂是有效治疗,无论HER2状态为低表达还是零表达。
- 二线药物在至停药时间方面无显著差异。
- 内分泌耐药肿瘤对CDK4/6抑制剂反应较差。
研究设计与样本
- GIM14/BIOMETA研究(NCT02284581)是意大利乳腺研究组(Gruppo Italiano Mammella)开展的一项回顾性/前瞻性研究,评估转移性乳腺癌的治疗模式和生存结局。
- 从GIM14-BIOMETA研究纳入的3832例患者中,筛选出701例接受一线CDK4/6抑制剂治疗的激素受体阳性/HER2阴性转移性乳腺癌患者。
主要发现
- 中位随访24.80个月时,HER2零表达与HER2低表达亚组的一线至停药时间分别为26.16个月(IQR 12.84-未达到)和27.60个月(IQR 12.12-64.44),p=0.972,无显著差异。
- HER2零表达与HER2低表达亚组的总生存分别为两组中位总生存均>60个月,p=0.398,无显著差异。
- 内分泌敏感亚组的中位至停药时间为33.24个月(IQR 16.32-未达到),继发内分泌耐药亚组为19.92个月(IQR 8.88-51.24),原发内分泌耐药亚组为17.40个月(IQR 7.44-24.72),p<0.001。
- 239例接受二线治疗的患者中,卡培他滨组二线至停药时间为6.11个月(IQR 2.96-11.47),紫杉类化疗组为5.06个月(IQR 2.99-9.99),依维莫司联合依西美坦组为5.39个月(IQR 2.53-9.03),氟维司群组为6.44个月(IQR 3.38-未达到),组间无显著差异(p=0.188)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to evaluate the effectiveness of CDK 4/6 inhibitors (CDK 4-6i) according to HER2 status (low/zero), and endocrine resistance/sensitivity, as well as the efficacy of second-line treatments, in a large real-world cohort. METHODS: The GIM14/BIOMETA study (NCT02284581) is a retrospective/prospective study of the Gruppo Italiano Mammella evaluating treatment patterns and survival outcomes in patients with metastatic breast cancer (MBC). We retrieved data on patients with hormone receptor-positive/HER2-negative MBC receiving first-line CDK 4/6i. RESULTS: Among 3832 patients enrolled in the GIM14-BIOMETA study, 701 were eligible. At a median follow-up of 24.80 months, no significant differences were found between HER2-zero and HER2-low subgroups in terms of first-line time to treatment discontinuation (TTD) (26.16 months [IQR 12.84-NR] vs. 27.60 months [IQR 12.12-64.44], p = 0.972) or overall survival (OS) (mOS>60 months for both groups, p = 0.398). Median TTD was 33.24 months (IQR 16.32-NR) for the endocrine sensitive subgroup, 19.92 months (IQR 8.88-51.24) for the secondary endocrine resistant subgroup and 17.40 months (IQR 7.44-24.72) for the primary endocrine resistant subset, respectively (p < 0.001). Among 239 patients receiving second-line treatment, no significant difference (p = 0.188) was found in terms of second-line TTD between those treated with capecitabine (6.11 months, IQR 2.96-11.47), taxane-based chemotherapy (5.06 months, IQR 2.99-9.99), everolimus plus exemestane (5.39 months, IQR 2.53-9.03) or fulvestrant (6.44 months, IQR 3.38-NR). CONCLUSIONS: Endocrine therapy plus CDK 4/6i represents an effective treatment, regardless of HER2 status (low/zero). Second-line agents did not differ significantly in terms of TTD. Endocrine resistant cancers exhibit poor response to CDK 4/6i.
引用
- Molinelli C, Bruzzone M, Blondeaux E, et al. The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study. Eur J Cancer. 2024. PMID: 39536433. doi:10.1016/j.ejca.2024.115113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。